{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:05:11Z","timestamp":1790053511214,"version":"4.0.1"},"reference-count":234,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Duchenne muscular dystrophy (DMD) arises from thousands of distinct mutations at a single X-linked locus that converge on loss of functional dystrophin, and this convergence on one molecular endpoint\u2014rather than any genetic uniformity\u2014has long made the disease appear a candidate for straightforward molecular correction. Three decades of work indicate that the difficulty lies less in restoring dystrophin than in restoring it adequately along four axes: amount, retained domains, breadth of coverage across skeletal muscle, diaphragm, heart and brain\u2014the constraint being extent of coverage rather than correctness of sarcolemmal localization, which these platforms achieve reliably\u2014and persistence in regenerating tissue. We argue that DMD is best understood as a systemic delivery problem superimposed on a progressive regenerative disorder, in which cargo design, biodistribution, cardiac coverage, immune response, disease stage and endpoint design jointly determine clinical benefit. AAV-microdystrophin has shown that body-wide expression is achievable, but delivers a truncated protein from an episomal genome at a dose whose upper bound was set by toxicity in other indications and whose minimum effective value was established in mdx mice rather than titrated in patients, leaving the therapeutic window better defined at its toxic than at its lower boundary. Exon skipping establishes that low-magnitude restoration is not trivial; genome editing addresses durability but adds integration risk; non-viral carriers permit redosing yet lack the potency required for a compartment comprising a third of body mass. Immunobiology constrains the field at several sequential levels, each now partially modifiable. Because the immunological burden of body-wide delivery can itself limit benefit, safety and efficacy are not fully separable, and progress is better judged by corrected muscle mass relative to immunological burden than by peak biopsy expression.<\/jats:p>","DOI":"10.3389\/fphar.2026.1930837","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:25:53Z","timestamp":1790051153000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["From molecular correction to functional rescue: delivery, tissue state, and immunobiology as the principal constraints on dystrophin-restoring therapy in Duchenne muscular dystrophy"],"prefix":"10.3389","volume":"17","author":[{"given":"Ke","family":"Li","sequence":"first","affiliation":[{"name":"Henan General Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Qi","sequence":"additional","affiliation":[{"name":"Zhengzhou Central Hospital Affiliated to Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyao","family":"Xin","sequence":"additional","affiliation":[{"name":"Henan General Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lun","family":"Qin","sequence":"additional","affiliation":[{"name":"Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Cheng","sequence":"additional","affiliation":[{"name":"Nancao Village Public Health Center","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yao","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital, Henan University of Chinese Medicine","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1089\/hum.2023.026","article-title":"The future of exon skipping for Duchenne muscular dystrophy","volume":"34","author":"Aartsma-Rus","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41582-018-0033-8","article-title":"Why dystrophin quantification is key in the eteplirsen Saga","volume":"14","author":"Aartsma-Rus","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/nat.2020.0845","article-title":"The 10th oligonucleotide therapy approved: Golodirsen for Duchenne muscular dystrophy","volume":"30","author":"Aartsma-Rus","year":"2020","journal-title":"Nucleic Acid. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"key":"B5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum. Mutat."},{"key":"B6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/nat.2017.0682","article-title":"Development of exon skipping therapies for Duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1152\/physrev.00007.2015","article-title":"Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy","volume":"96","author":"Allen","year":"2016","journal-title":"Physiol. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.echo.2018.10.017","article-title":"Speckle-tracking echocardiography in children with Duchenne muscular dystrophy: a prospective multicenter controlled cross-sectional study","volume":"32","author":"Amedro","year":"2019","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"13763","DOI":"10.1073\/pnas.1204638109","article-title":"Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery","volume":"109","author":"Aoki","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B11","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1089\/hum.2014.057","article-title":"Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material","volume":"25","author":"Ayuso","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1177\/0883073815570154","article-title":"Cognitive and neurobehavioral profile in boys with Duchenne muscular dystrophy","volume":"30","author":"Banihani","year":"2015","journal-title":"J. Child. Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1000958","DOI":"10.1371\/journal.pgen.1000958","article-title":"The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins","volume":"6","author":"Banks","year":"2010","journal-title":"PLoS Genet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1009179","DOI":"10.1371\/journal.pgen.1009179","article-title":"Microutrophin expression in dystrophic mice displays myofiber type differences in therapeutic effects","volume":"16","author":"Banks","year":"2020","journal-title":"PLoS Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.ymthe.2020.11.003","article-title":"Dystrophin gene-editing stability is dependent on dystrophin levels in skeletal but not cardiac muscles","volume":"29","author":"Bengtsson","year":"2021","journal-title":"Mol. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41598-020-57893-z","article-title":"Capsid-specific removal of circulating antibodies to adeno-associated virus vectors","volume":"10","author":"Bertin","year":"2020","journal-title":"Sci. Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological effects of givinostat in boys with Duchenne muscular dystrophy","volume":"26","author":"Bettica","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/mtna.2012.30","article-title":"Pip6-PMO, A new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment","volume":"1","author":"Betts","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1183101","DOI":"10.3389\/fphys.2023.1183101","article-title":"Duchenne muscular dystrophy: disease mechanism and therapeutic strategies","volume":"14","author":"Bez Batti Angulski","year":"2023","journal-title":"Front. Physiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1080\/14712598.2024.2394477","article-title":"The FDA approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy: a critical examination of the evidence and regulatory process","volume":"24","author":"Bhattacharyya","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"eabo1815","DOI":"10.1126\/scitranslmed.abo1815","article-title":"Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy","volume":"15","author":"Birch","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet. Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3389\/fimmu.2020.01293","article-title":"B cell depletion eliminates FVIII memory B cells and enhances AAV8-coF8 immune tolerance induction when combined with rapamycin","volume":"11","author":"Biswas","year":"2020","journal-title":"Front. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin immunity after gene therapy for Duchenne\u2019s muscular dystrophy","volume":"388","author":"B\u00f6nnemann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e2304","DOI":"10.1212\/WNL.0000000000012910","article-title":"Life expectancy in Duchenne muscular dystrophy: reproduced individual patient data meta-analysis","volume":"97","author":"Broomfield","year":"2021","journal-title":"Neurology"},{"key":"B231","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle Nerve"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1038\/s41591-025-03750-3","article-title":"AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial","volume":"31","author":"Butterfield","year":"2025","journal-title":"Nat. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/ng0593-77","article-title":"An alternative dystrophin transcript specific to peripheral nerve","volume":"4","author":"Byers","year":"1993","journal-title":"Nat. Genet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1016\/j.ymthe.2025.06.032","article-title":"Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy","volume":"33","author":"Byrne","year":"2025","journal-title":"Mol. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.3390\/ijms27031392","article-title":"Molecular bases of myopathies and their impact on clinical practice: advances and future perspectives","volume":"27","author":"Campuzano-Donoso","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"B31","first-page":"610","article-title":"X-linked dystrophies: from gene localization to gene therapy","volume":"5","author":"Chamberlain","year":"1992","journal-title":"Curr. Opin. Neurol. Neurosurg."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1093\/hmg\/11.20.2355","article-title":"Gene therapy of muscular dystrophy","volume":"11","author":"Chamberlain","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.1016\/j.ymthe.2025.08.029","article-title":"The future of gene therapy: safer vectors, sharper focus: high-profile failures demand deep root cause analysis - but the transformative potential of AAV remains within reach if the field is willing to learn and evolve","volume":"33","author":"Chamberlain","year":"2025","journal-title":"Mol. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2478\/bjmg-2013-0014","article-title":"Association between loss of dp140 and cognitive impairment in duchenne and becker dystrophies","volume":"16","author":"Chamova","year":"2013","journal-title":"Balk. J. Med. Genet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat. Neurosci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J. Hepatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41565-019-0539-2","article-title":"A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing","volume":"14","author":"Chen","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/mt.2013.244","article-title":"Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"11901","DOI":"10.3390\/ijms252211901","article-title":"Autophagy in muscle regeneration: mechanisms, targets, and therapeutic perspective","volume":"25","author":"Chu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet (London, England)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of Viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"14033","DOI":"10.1038\/mtm.2014.33","article-title":"B-Cell depletion is protective against Anti-AAV capsid immune response: a human subject case study","volume":"1","author":"Corti","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Costa Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1089\/hum.2023.119","article-title":"Understanding and tackling immune responses to Adeno-associated viral vectors","volume":"34","author":"Costa-Verdera","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1017\/s0012162201000913","article-title":"Intelligence and Duchenne muscular dystrophy: full-scale, verbal, and performance intelligence quotients","volume":"43","author":"Cotton","year":"2001","journal-title":"Dev. Med. Child. Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e208112","DOI":"10.1212\/WNL.0000000000208112","article-title":"Efficacy and safety of vamorolone over 48 weeks in boys with Duchenne muscular dystrophy: a randomized controlled trial","volume":"102","author":"Dang","year":"2024","journal-title":"Neurology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet. Neurol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/ana.25951","article-title":"Very low residual dystrophin quantity is associated with Milder Dystrophinopathy","volume":"89","author":"de Feraudy","year":"2021","journal-title":"Ann. Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/humu.20422","article-title":"Protein- and mRNA-based phenotype-genotype correlations in DMD\/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene","volume":"28","author":"Deburgrave","year":"2007","journal-title":"Hum. Mutat."},{"key":"B52","doi-asserted-by":"publisher","first-page":"11401","DOI":"10.1093\/nar\/gkac641","article-title":"Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice","volume":"50","author":"Desjardins","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e2109256118","DOI":"10.1073\/pnas.2109256118","article-title":"On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles","volume":"118","author":"Dilliard","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3389\/fmicb.2019.01570","article-title":"Accurate quantification and characterization of Adeno-associated viral vectors","volume":"10","author":"Dobnik","year":"2019","journal-title":"Front. Microbiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"12575","DOI":"10.1038\/s41598-017-12981-5","article-title":"Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy","volume":"7","author":"Doorenweerd","year":"2017","journal-title":"Sci. Rep."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/nm.3990","article-title":"Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division","volume":"21","author":"Dumont","year":"2015","journal-title":"Nat. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"16019","DOI":"10.1038\/mtm.2016.19","article-title":"Practical utilization of recombinant AAV vector reference standards: focus on vector genomes titration by free ITR qPCR","volume":"5","author":"D\u2019Costa","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B61","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/hmg\/4.5.837","article-title":"A novel dystrophin isoform is required for normal retinal electrophysiology","volume":"4","author":"D\u2019Souza","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"B62","doi-asserted-by":"publisher","first-page":"eabn4704","DOI":"10.1126\/sciadv.abn4704","article-title":"Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders","volume":"8","author":"El Andari","year":"2022","journal-title":"Sci. Adv."},{"key":"B63","doi-asserted-by":"publisher","first-page":"130544","DOI":"10.1016\/j.ijbiomac.2024.130544","article-title":"A review on mechanistic insights into structure and function of dystrophin protein in pathophysiology and therapeutic targeting of Duchenne muscular dystrophy","volume":"264","author":"Elasbali","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e139881","DOI":"10.1172\/jci.insight.139881","article-title":"Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme","volume":"5","author":"Elmore","year":"2020","journal-title":"JCI Insight"},{"key":"B65","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"publisher","first-page":"gkaf241","DOI":"10.1093\/nar\/gkaf241","article-title":"AOC 1044 induces exon 44 skipping and restores dystrophin protein in preclinical models of Duchenne muscular dystrophy","volume":"53","author":"Etxaniz","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/hgtb.2011.104","article-title":"Systemic errors in quantitative polymerase chain reaction titration of self-complementary adeno-associated viral vectors and improved alternative methods","volume":"23","author":"Fagone","year":"2012","journal-title":"Hum. Gene Ther. Methods"},{"key":"B68","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1","volume":"225","author":"Feldman","year":"2020","journal-title":"J. Pediatr."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/(sici)1097-0258(19990615)18:11<1341::aid-sim129>3.0.co;2-7","article-title":"Combining mortality and longitudinal measures in clinical trials","volume":"18","author":"Finkelstein","year":"1999","journal-title":"Stat. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.2147\/JMDH.S458181","article-title":"Healthcare stakeholder perspectives on a value assessment approach for Duchenne muscular dystrophy therapies","volume":"17","author":"Fischer","year":"2024","journal-title":"J. Multidiscip. Healthc."},{"key":"B71","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.omtm.2022.08.009","article-title":"A first-in-human phase I\/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2","volume":"27","author":"Flanigan","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B72","doi-asserted-by":"publisher","first-page":"5447","DOI":"10.1007\/s00018-021-03862-2","article-title":"The multifaceted view of heart problem in Duchenne muscular dystrophy","volume":"78","author":"Florczyk-Soluch","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3390\/cells14120892","article-title":"Multi-modal analysis of satellite cells reveals early impairments at pre-contractile stages of myogenesis in Duchenne muscular dystrophy","volume":"14","author":"Franzmeier","year":"2025","journal-title":"Cells"},{"key":"B76","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1089\/hgtb.2019.031","article-title":"Two-dimensional droplet digital PCR as a tool for titration and integrity evaluation of recombinant Adeno-associated viral vectors","volume":"30","author":"Furuta-Hanawa","year":"2019","journal-title":"Hum. Gene Ther. Methods"},{"key":"B77","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.omtn.2022.08.019","article-title":"A cell-penetrating peptide enhances delivery and efficacy of phosphorodiamidate morpholino oligomers in mdx mice","volume":"30","author":"Gan","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3390\/cells13141168","article-title":"Cardiomyopathy in Duchenne muscular dystrophy and the potential for mitochondrial therapeutics to improve treatment response","volume":"13","author":"Gandhi","year":"2024","journal-title":"Cells"},{"key":"B79","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"17562864221149780","DOI":"10.1177\/17562864221149781","article-title":"Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy","volume":"16","author":"Goedeker","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B81","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.nmd.2017.10.004","article-title":"A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy","volume":"28","author":"Goemans","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"B82","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","article-title":"AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset","volume":"25","author":"Goertsen","year":"2022","journal-title":"Nat. Neurosci."},{"key":"B83","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41434-025-00531-y","article-title":"Is dystrophin immunogenicity a barrier to advancing gene therapy for Duchenne muscular dystrophy?","volume":"32","author":"G\u00f3recki","year":"2025","journal-title":"Gene Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1073\/pnas.95.9.4929","article-title":"Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs","volume":"95","author":"Gorman","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1126\/science.1104297","article-title":"Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping","volume":"306","author":"Goyenvalle","year":"2004","journal-title":"Science"},{"key":"B86","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nm.3765","article-title":"Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers","volume":"21","author":"Goyenvalle","year":"2015","journal-title":"Nat. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41419-025-07755-1","article-title":"Muscle stem cells in Duchenne muscular dystrophy exhibit molecular impairments and altered cell fate trajectories impacting regenerative capacity","volume":"16","author":"Granet","year":"2025","journal-title":"Cell Death Dis."},{"key":"B232","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","article-title":"Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy","volume":"87","author":"Griggs","year":"2016","journal-title":"Neurology"},{"key":"B233","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jama.2022.4315","article-title":"Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy: a randomized clinical trial","volume":"327","author":"Guglieri","year":"2022","journal-title":"JAMA"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.amjcard.2009.12.070","article-title":"Detection of progressive cardiac dysfunction by serial evaluation of circumferential strain in patients with Duchenne muscular dystrophy","volume":"105","author":"Hagenbuch","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1080\/15476286.2021.1874161","article-title":"Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing","volume":"18","author":"Hanson","year":"2021","journal-title":"RNA Biol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"23488","DOI":"10.1038\/s41598-024-70783-y","article-title":"Safety and efficacy of viltolarsen in ambulatory and nonambulatory males with Duchenne muscular dystrophy","volume":"14","author":"Harper","year":"2024","journal-title":"Sci. Rep."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e165869","DOI":"10.1172\/jci.insight.165869","article-title":"Potential limitations of microdystrophin gene therapy for Duchenne muscular dystrophy","volume":"9","author":"Hart","year":"2024","journal-title":"JCI Insight"},{"key":"B92","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1177\/0883073807309775","article-title":"Neuropsychiatric disorders in males with Duchenne muscular dystrophy: frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive--compulsive disorder","volume":"23","author":"Hendriksen","year":"2008","journal-title":"J. Child. Neurol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in Nonhuman Primates and piglets following high-dose intravenous administration of an Adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jacc.2008.12.032","article-title":"Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular dystrophy: a cardiac magnetic resonance tagging study","volume":"53","author":"Hor","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1532-429X-15-107","article-title":"Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function","volume":"15","author":"Hor","year":"2013","journal-title":"J. Cardiovasc. Magn. Reson. Off. J. Soc. Cardiovasc. Magn. Reson."},{"key":"B96","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","article-title":"The neurotropic properties of AAV-PHP.B are limited to C57BL\/6J mice","volume":"26","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene Moxeparvovec: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"B99","doi-asserted-by":"publisher","first-page":"e230086","DOI":"10.57264\/cer-2023-0086","article-title":"Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA","volume":"12","author":"Iff","year":"2023","journal-title":"J. Comp. Eff. Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/mus.28075","article-title":"Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls","volume":"70","author":"Iff","year":"2024","journal-title":"Muscle Nerve"},{"key":"B101","doi-asserted-by":"publisher","first-page":"eabd0321","DOI":"10.1126\/sciadv.abd0321","article-title":"Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles","volume":"7","author":"Ilyinskii","year":"2021","journal-title":"Sci. Adv."},{"key":"B102","volume-title":"Beyond the cut: Long-Read Sequencing Reveals Complex Genomic and Transcriptomic Changes in AAV-CRISPR Therapy for Duchenne Muscular Dystrophy","author":"Jia","year":"2025"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737175.2025.2462281","article-title":"The latest developments in synthetic approaches to Duchenne muscular dystrophy","volume":"25","author":"Johnson","year":"2025","journal-title":"Expert Rev. Neurother."},{"key":"B104","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1056\/NEJMoa1612567","article-title":"IgG endopeptidase in highly sensitized patients undergoing transplantation","volume":"377","author":"Jordan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine","volume":"16","author":"Ju","year":"2022","journal-title":"ACS Nano"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1016\/j.jacc.2016.02.081","article-title":"Dystrophin-deficient cardiomyopathy","volume":"67","author":"Kamdar","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-073192","article-title":"Evidence regarding Duchenne muscular dystrophy newborn screening","author":"Kemper","year":"2025","journal-title":"Pediatrics"},{"key":"B108","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","article-title":"Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice","volume":"12","author":"Kenjo","year":"2021","journal-title":"Nat. Commun."},{"key":"B109","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2018.10.005","article-title":"Micro-utrophin improves cardiac and skeletal muscle function of severely affected D2\/mdx mice","volume":"11","author":"Kennedy","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B110","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3389\/fimmu.2020.00969","article-title":"Development of ImmTOR tolerogenic nanoparticles for the mitigation of anti-drug antibodies","volume":"11","author":"Kishimoto","year":"2020","journal-title":"Front. Immunol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/14712598.2022.2060737","article-title":"Addressing high dose AAV toxicity - \u201cone and done\u201d or \u201cslower and lower\u201d","volume":"22","author":"Kishimoto","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"B112","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1046\/j.1460-9568.1999.00887.x","article-title":"Short communication: altered synaptic clustering of GABAA receptors in mice lacking dystrophin (mdx mice)","volume":"11","author":"Knuesel","year":"1999","journal-title":"Eur. J. Neurosci."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1180980","DOI":"10.3389\/fphys.2023.1180980","article-title":"Satellite cell contribution to disease pathology in Duchenne muscular dystrophy","volume":"14","author":"Kodippili","year":"2023","journal-title":"Front. Physiol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell"},{"key":"B115","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0092-8674(88)90383-2","article-title":"The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein","volume":"53","author":"Koenig","year":"1988","journal-title":"Cell"},{"key":"B116","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","author":"Kozma","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B117","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/322073a0","article-title":"Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy","volume":"322","author":"Kunkel","year":"1986","journal-title":"Nature"},{"key":"B118","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.omtm.2020.09.016","article-title":"In vivo gene editing of muscle stem cells with adeno-associated viral vectors in a mouse model of Duchenne muscular dystrophy","volume":"19","author":"Kwon","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B119","doi-asserted-by":"publisher","first-page":"12140","DOI":"10.1021\/acsnano.8b05721","article-title":"Dystrophin as a molecular shock absorber","volume":"12","author":"Le","year":"2018","journal-title":"ACS Nano"},{"key":"B120","doi-asserted-by":"publisher","first-page":"16105","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy","volume":"8","author":"Le Guiner","year":"2017","journal-title":"Nat. Commun."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/mt.2013.121","article-title":"AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy","volume":"21","author":"Le Hir","year":"2013","journal-title":"Mol. Ther."},{"key":"B122","doi-asserted-by":"publisher","first-page":"103780","DOI":"10.1016\/j.cellimm.2018.03.004","article-title":"Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne muscular dystrophy patients","volume":"342","author":"Leborgne","year":"2019","journal-title":"Cell. Immunol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat. Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"00176-2023","DOI":"10.1183\/23120541.00176-2023","article-title":"Cardiomyopathy as cause of death in Duchenne muscular dystrophy: a longitudinal observational study","volume":"9","author":"Lechner","year":"2023","journal-title":"ERJ Open Res."},{"key":"B125","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/349334a0","article-title":"Expression of recombinant dystrophin and its localization to the cell membrane","volume":"349","author":"Lee","year":"1991","journal-title":"Nature"},{"key":"B126","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","article-title":"Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair","volume":"1","author":"Lee","year":"2017","journal-title":"Nat. Biomed. Eng."},{"key":"B127","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/6981","article-title":"Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences","volume":"17","author":"Li","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1242\/jcs.064808","article-title":"Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin","volume":"123","author":"Li","year":"2010","journal-title":"J. Cell Sci."},{"key":"B129","doi-asserted-by":"publisher","first-page":"e162809","DOI":"10.1172\/JCI162809","article-title":"Mini-dCas13X-mediated RNA editing restores dystrophin expression in a humanized mouse model of Duchenne muscular dystrophy","volume":"133","author":"Li","year":"2023","journal-title":"J. Clin. Invest."},{"key":"B130","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/hmg\/4.3.329","article-title":"Dp140: a novel 140 kDa CNS transcript from the dystrophin locus","volume":"4","author":"Lidov","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"B131","doi-asserted-by":"publisher","first-page":"e2112546119","DOI":"10.1073\/pnas.2112546119","article-title":"Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy","volume":"119","author":"Lim","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B132","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1126\/science.adp8179","article-title":"Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies","volume":"386","author":"Lindley","year":"2024","journal-title":"Science"},{"key":"B133","doi-asserted-by":"publisher","first-page":"101411","DOI":"10.1016\/j.omtm.2025.101411","article-title":"Systemic delivery of AAV5, AAV8, and AAV9 packaging a C5-12-microdystrophin-FLAG expression cassette in non-human primates","volume":"33","author":"Liu","year":"","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/s41586-024-08324-w","article-title":"Native DGC structure rationalizes muscular dystrophy-causing mutations","volume":"637","author":"Liu","year":"","journal-title":"Nature"},{"key":"B135","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3390\/genes17050533","article-title":"Current and emerging therapeutic strategies for the treatment of Duchenne muscular dystrophy","volume":"17","author":"Lopez Perez","year":"2026","journal-title":"Genes (Basel)"},{"key":"B136","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ymthe.2018.11.018","article-title":"mRNA-Based protein replacement therapy for the heart","volume":"27","author":"Magadum","year":"2019","journal-title":"Mol. Ther."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.ymthe.2017.05.003","article-title":"Successful repeated hepatic gene delivery in mice and non-human Primates achieved by sequential administration of AAV5(ch) and AAV1","volume":"25","author":"Majowicz","year":"2017","journal-title":"Mol. Ther."},{"key":"B234","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1161\/CIRCULATIONAHA.114.015151","article-title":"Contemporary cardiac issues in Duchenne muscular dystrophy. Working group of the national heart, lung, and blood institute in collaboration with parent project muscular dystrophy","volume":"131","author":"McNally","year":"2015","journal-title":"Circulation"},{"key":"B139","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat. Commun."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne\u2019s muscular dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B141","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1167762","DOI":"10.3389\/fcell.2023.1167762","article-title":"Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy","volume":"11","author":"Mendell","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat. Med."},{"key":"B146","doi-asserted-by":"publisher","first-page":"e0160195","DOI":"10.1371\/journal.pone.0160195","article-title":"Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy","volume":"11","author":"Mercuri","year":"2016","journal-title":"PLoS One"},{"key":"B147","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet. Neurol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet. Neurol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","article-title":"Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the society for cardiovascular magnetic resonance (SCMR) endorsed by the European association for cardiovascular imag","volume":"19","author":"Messroghli","year":"2017","journal-title":"J. Cardiovasc. Magn. Reson. Off. J. Soc. Cardiovasc. Magn. Reson."},{"key":"B150","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.3390\/ijms20174098","article-title":"Cardiac pathophysiology and the future of cardiac therapies in Duchenne muscular dystrophy","volume":"20","author":"Meyers","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/mt.2012.84","article-title":"Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B","volume":"20","author":"Mingozzi","year":"2012","journal-title":"Mol. Ther."},{"key":"B152","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3233\/JND-210665","article-title":"A combined prospective and retrospective comparison of long-term functional outcomes suggests delayed loss of ambulation and pulmonary decline with long-term Eteplirsen treatment","volume":"9","author":"Mitelman","year":"2022","journal-title":"J. Neuromuscul. Dis."},{"key":"B153","doi-asserted-by":"publisher","first-page":"9674","DOI":"10.1038\/s41598-022-13405-9","article-title":"Muscle regeneration affects Adeno associated virus 1 mediated transgene transcription","volume":"12","author":"Mollard","year":"2022","journal-title":"Sci. Rep."},{"key":"B154","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"key":"B155","doi-asserted-by":"publisher","first-page":"6742","DOI":"10.3390\/ijms26146742","article-title":"Duchenne muscular dystrophy: integrating current clinical practice with future therapeutic and diagnostic Horizons","volume":"26","author":"Montagna","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B156","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1038\/mt.2011.108","article-title":"A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8","volume":"19","author":"Monteilhet","year":"2011","journal-title":"Mol. Ther."},{"key":"B157","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41586-021-03770-2","article-title":"Regulated control of gene therapies by drug-induced splicing","volume":"596","author":"Monteys","year":"2021","journal-title":"Nature"},{"key":"B158","doi-asserted-by":"publisher","first-page":"S317","DOI":"10.3233\/JND-210683","article-title":"Changes in myonuclear number during postnatal growth - implications for AAV gene therapy for muscular dystrophy","volume":"8","author":"Morgan","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"B159","doi-asserted-by":"publisher","first-page":"e2206324120","DOI":"10.1073\/pnas.2206324120","article-title":"Dystrophin myonuclear domain restoration governs treatment efficacy in dystrophic muscle","volume":"120","author":"Morin","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B160","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","article-title":"Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy","volume":"1798","author":"Moulton","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"B161","doi-asserted-by":"publisher","first-page":"103479","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"key":"B162","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.nmd.2007.07.005","article-title":"Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human","volume":"17","author":"Neri","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"B163","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12968-016-0292-8","article-title":"Native T1 values identify myocardial changes and stratify disease severity in patients with Duchenne muscular dystrophy","volume":"18","author":"Olivieri","year":"2016","journal-title":"J. Cardiovasc. Magn. Reson. Off. J. Soc. Cardiovasc. Magn. Reson."},{"key":"B164","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.omtm.2020.01.004","article-title":"Successful transduction with AAV vectors after selective depletion of Anti-AAV antibodies by immunoadsorption","volume":"16","author":"Orlowski","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B165","doi-asserted-by":"publisher","first-page":"e213604","DOI":"10.1212\/WNL.0000000000213604","article-title":"Delandistrogene Moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy: evidence in focus: report of the AAN guidelines subcommittee","volume":"104","author":"Oskoui","year":"2025","journal-title":"Neurology"},{"key":"B166","doi-asserted-by":"publisher","first-page":"102901","DOI":"10.1016\/j.omtn.2026.102901","article-title":"AAV-mediated gene transfer of a novel microdystrophin ameliorates pathology and enhances muscle function in a mouse model of DMD","volume":"37","author":"Owusu","year":"2026","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B167","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41536-025-00445-8","article-title":"Disease exacerbation in human DMD MYOrganoids enables gene therapy evaluation and unveils persistence of fibrotic activity","volume":"11","author":"Palmieri","year":"2026","journal-title":"NPJ Regen. Med."},{"key":"B168","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jpeds.2012.03.020","article-title":"Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation","volume":"161","author":"Pane","year":"2012","journal-title":"J. Pediatr."},{"key":"B169","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00439-025-02758-6","article-title":"Efficacy of delandistrogene moxeparvovec on Duchenne muscular dystrophy: a systematic review and meta-analysis","volume":"144","author":"Pascual-Morena","year":"2025","journal-title":"Hum. Genet."},{"key":"B170","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/hmg\/4.8.1251","article-title":"Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice","volume":"4","author":"Phelps","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"B171","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1089\/hum.2024.53426.bfs","article-title":"Boy dosed with Pfizer\u2019s Duchenne muscular dystrophy gene therapy dies a year after phase II trial","volume":"36","author":"Philippidis","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"B172","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1089\/hum.2019.255","article-title":"Dose-escalation study of systemically delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx mouse model of Duchenne muscular dystrophy","volume":"32","author":"Potter","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"B173","doi-asserted-by":"publisher","first-page":"101195","DOI":"10.1016\/j.omtm.2024.101195","article-title":"Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74","volume":"32","author":"Potter","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B174","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41598-024-84077-w","article-title":"Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy","volume":"15","author":"Potter","year":"2025","journal-title":"Sci. Rep."},{"key":"B175","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat. Med."},{"key":"B176","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1474-4422(14)70318-7","article-title":"Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial","volume":"14","author":"Raman","year":"2015","journal-title":"Lancet. Neurol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ymthe.2019.01.002","article-title":"Development of novel micro-dystrophins with enhanced functionality","volume":"27","author":"Ramos","year":"2019","journal-title":"Mol. Ther."},{"key":"B178","doi-asserted-by":"publisher","first-page":"101216","DOI":"10.1016\/j.omtm.2024.101216","article-title":"B cell focused transient immune suppression protocol for efficient AAV readministration to the liver","volume":"32","author":"Rana","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B179","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.omtn.2017.06.013","article-title":"Efficacy and safety profile of Tricyclo-DNA antisense oligonucleotides in Duchenne muscular dystrophy mouse model","volume":"8","author":"Relizani","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B180","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/dmcn.12922","article-title":"Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations","volume":"58","author":"Ricotti","year":"2016","journal-title":"Dev. Med. Child. Neurol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"101160","DOI":"10.1016\/j.omtm.2023.101160","article-title":"Long-term dystrophin restoration supports development of splice correction therapy for DMD patients with exon 2 duplications","volume":"31","author":"Roberts","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B182","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41573-023-00775-6","article-title":"Therapeutic approaches for Duchenne muscular dystrophy","volume":"22","author":"Roberts","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"B183","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-0716-2772-3_2","article-title":"Viltolarsen: from preclinical studies to FDA approval","volume":"2587","author":"Roshmi","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"E9944","DOI":"10.1073\/pnas.1811276115","article-title":"High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing","volume":"115","author":"Sago","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B185","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/10430342251385586","article-title":"Enhancing AAV9-UF\u03bcDys1 gene therapy efficacy through immunosuppression in mice with pre-existing immunity and enabling redosing strategies for Duchenne muscular dystrophy","volume":"37","author":"Saha","year":"2026","journal-title":"Hum. Gene Ther."},{"key":"B186","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1182\/bloodadvances.2019000380","article-title":"Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates","volume":"3","author":"Salas","year":"2019","journal-title":"Blood Adv."},{"key":"B187","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/sj.mt.6300027","article-title":"Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle","volume":"15","author":"Salva","year":"2007","journal-title":"Mol. Ther."},{"key":"B188","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3390\/pathogens12111301","article-title":"Transcriptional targeting approaches in cardiac gene transfer using AAV vectors","volume":"12","author":"Schr\u00f6der","year":"2023","journal-title":"Pathog. (Basel, Switzerland)"},{"key":"B189","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1007\/s00018-004-4190-0","article-title":"The special Sm core structure of the U7 snRNP: far-reaching significance of a small nuclear ribonucleoprotein","volume":"61","author":"Sch\u00fcmperli","year":"2004","journal-title":"Cell. Mol. Life Sci."},{"key":"B190","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/brain\/awn253","article-title":"A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice","volume":"132","author":"Sekiguchi","year":"2009","journal-title":"Brain"},{"key":"B191","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.nmd.2023.09.008","article-title":"261st ENMC international workshop: management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, the Netherlands","volume":"33","author":"Servais","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"B192","doi-asserted-by":"publisher","first-page":"1001263","DOI":"10.3389\/fimmu.2022.1001263","article-title":"rAAV immunogenicity, toxicity, and durability in 255 clinical trials: a meta-analysis","volume":"13","author":"Shen","year":"2022","journal-title":"Front. Immunol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1016\/j.ymthe.2025.06.031","article-title":"Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchenne muscular dystrophy: initial observations from a phase 1b trial","volume":"33","author":"Sherlock","year":"2025","journal-title":"Mol. Ther."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","article-title":"Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial","volume":"22","author":"Shieh","year":"2023","journal-title":"Lancet. Neurol."},{"key":"B195","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/jamacardio.2016.4801","article-title":"Myocardial fibrosis progression in duchenne and becker muscular dystrophy: a randomized clinical trial","volume":"2","author":"Silva","year":"2017","journal-title":"JAMA Cardiol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.omtm.2021.03.014","article-title":"Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated DMD exon 2 skipping","volume":"21","author":"Simmons","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B197","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1097\/MS9.0000000000002146","article-title":"Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR\/Cas9 gene therapy for sickle cell disease","volume":"86","author":"Singh","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"B198","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.neubiorev.2013.03.016","article-title":"Neuropsychological and neurobehavioral functioning in Duchenne muscular dystrophy: a review","volume":"37","author":"Snow","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"B199","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/s41591-019-0594-0","article-title":"Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models","volume":"25","author":"Song","year":"2019","journal-title":"Nat. Med."},{"key":"B200","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12968-016-0224-7","article-title":"Increased myocardial native T1 and extracellular volume in patients with Duchenne muscular dystrophy","volume":"18","author":"Soslow","year":"2016","journal-title":"J. Cardiovasc. Magn. Reson. Off. J. Soc. Cardiovasc. Magn. Reson."},{"key":"B201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2016.06.036","article-title":"Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles","volume":"237","author":"Sugo","year":"2016","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"B202","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41586-024-07710-8","article-title":"Split intein-mediated protein trans-splicing to express large dystrophins","volume":"632","author":"Tasfaout","year":"2024","journal-title":"Nature"},{"key":"B203","doi-asserted-by":"publisher","first-page":"e189075","DOI":"10.1172\/JCI189075","article-title":"Expression of full-length dystrophin reverses muscular dystrophy defects in young and old mdx4cv mice","volume":"135","author":"Tasfaout","year":"2025","journal-title":"J. Clin. Invest."},{"key":"B204","doi-asserted-by":"publisher","first-page":"r1548","DOI":"10.1136\/bmj.r1548","article-title":"Duchenne gene therapy halted after three deaths and company u turn","volume":"390","author":"Taylor","year":"2025","journal-title":"BMJ"},{"key":"B205","doi-asserted-by":"crossref","DOI":"10.64898\/2026.05.22.727055","volume-title":"Neuronal Targeted AAV Micro-Dystrophin Restores Neurobehavioural Co-Morbidities, Grip Strength and Motor Coordination in mdx52 Mouse Model of Duchenne Muscular Dystrophy","author":"Tetorou","year":"2026"},{"key":"B206","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/mt.2008.52","article-title":"Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle","volume":"16","author":"Townsend","year":"2008","journal-title":"Mol. Ther."},{"key":"B207","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tcm.2009.04.006","article-title":"Cardiac consequences to skeletal muscle-centric therapeutics for Duchenne muscular dystrophy","volume":"19","author":"Townsend","year":"2009","journal-title":"Trends cardiovasc. Med."},{"key":"B208","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/mt.2015.193","article-title":"Myocardial delivery of lipidoid nanoparticle carrying modRNA induces rapid and transient expression","volume":"24","author":"Turnbull","year":"2016","journal-title":"Mol. Ther."},{"key":"B209","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/hmg\/ddx013","article-title":"Relationships linking emotional, motor, cognitive and GABAergic dysfunctions in dystrophin-deficient mdx mice","volume":"26","author":"Vaillend","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"B210","doi-asserted-by":"publisher","first-page":"e0249472","DOI":"10.1371\/journal.pone.0249472","article-title":"Impact of estrogen deficiency on diaphragm and leg muscle contractile function in female mdx mice","volume":"16","author":"Vang","year":"2021","journal-title":"PLoS One"},{"key":"B211","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.omtm.2017.01.003","article-title":"Effective depletion of pre-existing Anti-AAV antibodies requires broad immune targeting","volume":"4","author":"Velazquez","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B212","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1089\/hum.2022.081","article-title":"Seroprevalence of adeno-associated virus neutralizing antibodies in males with Duchenne muscular dystrophy","volume":"34","author":"Verma","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"B213","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S1474-4422(14)70195-4","article-title":"Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study","volume":"13","author":"Voit","year":"2014","journal-title":"Lancet. Neurol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00246-020-02372-5","article-title":"Troponin I levels correlate with cardiac MR LGE and native T1 values in Duchenne muscular dystrophy cardiomyopathy and identify early disease progression","volume":"41","author":"Voleti","year":"2020","journal-title":"Pediatr. Cardiol."},{"key":"B215","doi-asserted-by":"publisher","first-page":"7965","DOI":"10.1038\/s41467-024-52002-4","article-title":"An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species","volume":"15","author":"Vu Hong","year":"2024","journal-title":"Nat. Commun."},{"key":"B216","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1038\/mt.2012.181","article-title":"Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping","volume":"20","author":"Vulin","year":"2012","journal-title":"Mol. Ther."},{"key":"B217","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2217\/bmm-2021-0222","article-title":"Safety and disease monitoring biomarkers in Duchenne muscular dystrophy: results from a phase II trial","volume":"15","author":"Wagner","year":"2021","journal-title":"Biomark. Med."},{"key":"B218","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.tins.2012.04.004","article-title":"The dystrophin-glycoprotein complex in brain development and disease","volume":"35","author":"Waite","year":"2012","journal-title":"Trends Neurosci."},{"key":"B219","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/s41586-024-08310-2","article-title":"Structure and assembly of the dystrophin glycoprotein complex","volume":"637","author":"Wan","year":"2025","journal-title":"Nature"},{"key":"B220","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/gt.2008.104","article-title":"Construction and analysis of compact muscle-specific promoters for AAV vectors","volume":"15","author":"Wang","year":"2008","journal-title":"Gene Ther."},{"key":"B221","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1089\/hum.2022.180","article-title":"The implication of Hinge 1 and Hinge 4 in micro-dystrophin gene therapy for Duchenne muscular dystrophy","volume":"34","author":"Wasala","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"B222","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1038\/s41467-020-17029-3","article-title":"Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing","volume":"11","author":"Wei","year":"2020","journal-title":"Nat. Commun."},{"key":"B223","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/nm.3628","article-title":"Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice","volume":"20","author":"Wein","year":"2014","journal-title":"Nat. Med."},{"key":"B224","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1089\/hgtb.2015.013","article-title":"Systematic comparison and validation of quantitative real-time PCR methods for the quantitation of adeno-associated viral products","volume":"26","author":"Werling","year":"2015","journal-title":"Hum. Gene Ther. Methods"},{"key":"B225","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1089\/hum.2020.182","article-title":"Moving forward after two deaths in a gene therapy trial of myotubular myopathy","volume":"31","author":"Wilson","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"B226","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/mt.2013.268","article-title":"AAV empty capsids: for better or for worse?","volume":"22","author":"Wright","year":"2014","journal-title":"Mol. Ther."},{"key":"B227","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/ana.26755","article-title":"Delandistrogene Moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8 years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR)","volume":"94","author":"Zaidman","year":"2023","journal-title":"Ann. Neurol."},{"key":"B228","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ana.26409","article-title":"Partial restoration of brain dystrophin and behavioral deficits by exon skipping in the muscular dystrophy X-Linked (mdx) mouse","volume":"92","author":"Zarrouki","year":"2022","journal-title":"Ann. Neurol."},{"key":"B229","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1038\/s41467-024-50569-6","article-title":"Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat. Commun."},{"key":"B230","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1930837\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:25:56Z","timestamp":1790051156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1930837\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":234,"alternative-id":["10.3389\/fphar.2026.1930837"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1930837","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1930837"}}